Monoclonal antibody detection plate, monoclonal antibody detection kit and efficient monoclonal antibody screening method

The antigen protein was immobilized on the ELISA plate through SpyCatcher/Spytag protein chemical reaction, which solved the problem of low binding efficiency caused by antigen coating, and significantly improved the screening efficiency and number of positive antibodies of monoclonal antibodies.

CN118914554APending Publication Date: 2024-11-08HENAN CELNOVTE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410974842.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is less efficient in the monoclonal antibody screening process, mainly because the antigen is coated on the ELISA plate, causing adsorption of some regions, affecting the binding of the antibody to the antigen, resulting in a decrease in the number of positive monoclonal antibodies and prolonging the screening cycle.

Method used

SpyCatcher/Spytag protein chemical reaction is used to fix the antigen protein on the ELISA plate, keeping it a certain distance from the bottom plate, maintaining the complete conformation of the antigen epitope, thereby improving the binding efficiency of the antibody and antigen.

Benefits of technology

The screening efficiency of monoclonal antibodies is significantly improved, the repeated screening work is reduced, the binding ability of antibodies to antigens is enhanced, and the number of positive monoclonal antibodies screened is improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118914554A_ABST
    Figure CN118914554A_ABST
Patent Text Reader

Abstract

The invention relates to a monoclonal antibody detection plate, a detection kit and an efficient screening method of monoclonal antibodies, and belongs to the technical field of bioengineering. The monoclonal antibody detection plate disclosed by the invention comprises a SpyCatcher protein and a Spytag, wherein the SpyCatcher protein is coated on the detection plate, and the Spytag is coupled with the SpyCatcher protein; the Spytag is connected with an antigen protein. The invention also provides a monoclonal antibody detection kit and an efficient screening method of the monoclonal antibody. According to the screening method disclosed by the invention, the antigen protein is indirectly fixed on the ELISA plate by utilizing a peptide-protein chemical reaction generated by SpyCatcher protein and Spytag, so that a certain distance is formed between the antigen protein and the bottom of the detection plate, the epitope of the antigen is kept complete, and the problem that the antigen is coated in a hybridoma screening process to cause that the epitope is covered and the antibody combination is influenced can be effectively solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a monoclonal antibody detection plate, a detection kit and a high-efficiency screening method for monoclonal antibodies, and belongs to the technical field of bioengineering. Background Art

[0002] Hybridoma technique, also known as lymphocyte hybridoma technique, is also called monoclonal antibody technique. It is developed on the basis of somatic cell fusion technique. Scientists Georges Kohler and Cesar Milstein discovered that hybridoma cells formed by fusion of mouse myeloma cells and spleen cells of immunized mice in vitro have the characteristics of unlimited reproduction of myeloma cells and the characteristics of antibody-forming cells in synthesizing and secreting specific antibodies. Monoclonal antibodies are antibodies secreted by the proliferation of a hybridoma cell, which have the advantages of being highly uniform and targeting only a specific antigen epitope. Currently, hybridoma technique is the main method for preparing monoclonal antibodies.

[0003] The brief process of hybridoma technology is as follows: mouse myeloma cells are fused with mouse spleen cells (mainly B lymphocytes), the fused cells are plated, and HAT selective medium (a myeloma defective medium) is added for screening. Myeloma cells cannot survive, and spleen cells can only survive for 7-10 days under in vitro conditions. In the end, only myeloma cells (i.e., hybridoma cells) fused with lymphocytes survive. At this time, when the clone grows to a certain size, that is, when the antibodies enriched in the supernatant meet the screening process, the screening of hybridomas is carried out. Usually, ELISA is used to screen hybridoma cell lines with binding specific antigens. However, in most cases, the obtained cell lines are mixed cell lines, and further screening and culture are required to obtain monoclonal cell lines. At this time, the standard further screening method is limited dilution, which is simple and easy to operate and does not require other equipment to assist, but its screening is time-consuming and labor-intensive, and in the process of subcloning, positive cell lines may be lost.

[0004] In order to overcome the defects of the traditional limiting dilution method, Davis et al. constructed a semi-solid culture medium using methylcellulose, so that hybridomas can effectively form single-cell colonies in the semi-solid culture medium. Compared with the traditional limiting dilution method, the fused cells are separated from each other and grow in colonies when using the semi-solid culture medium to clone hybridoma cells. They do not interfere with each other or mix with each other, and the separation of monoclonal clones can be completed in one step. After the screened single hybridoma cells are expanded and cultured, the specificity of the single hybridoma to the antigen is verified by ELISA. However, the commonly used ELISA verification is to coat the screening antigen on the ELISA plate. The coating process will cause part of the antigen area to be adsorbed on the ELISA plate, resulting in some antibody epitopes bound to the area being covered, affecting the binding of the monoclonal antibody to the antigen, and ultimately affecting the number of positive monoclonal antibodies screened. From the side, it also leads to a longer cycle for screening the target antibody, resulting in low screening efficiency. Summary of the invention

[0005] The first object of the present invention is to provide a monoclonal antibody detection plate, which provides an efficient screening tool for the screening of monoclonal antibodies in the prior art.

[0006] The second object of the present invention is to provide a monoclonal antibody detection kit to provide an efficient screening tool for the screening of monoclonal antibodies in the prior art.

[0007] The third object of the present invention is to provide an efficient screening method for monoclonal antibodies to solve the problem of low efficiency in the monoclonal antibody screening process in the prior art.

[0008] In order to achieve the above object, the technical solution of a monoclonal antibody detection plate of the present invention is:

[0009] A monoclonal antibody detection plate comprises a SpyCatcher protein coated on the detection plate and a Spytag coupled to the SpyCatcher protein; the Spytag is connected to an antigen protein.

[0010] The beneficial effect of the above scheme is that the monoclonal antibody detection plate of the present invention is a pioneering invention. After a lot of research and experiments, the present invention found that the antigen protein is fixed on the ELISA plate by the peptide-protein chemical reaction generated by SpyCatcher / Spytag, which can keep a certain distance between the antigen protein and the bottom plate, so that the antigen epitope is fully exposed. In addition, the binding of the antibody to the antigen is not affected by the bottom of the ELISA plate, and a certain distance is maintained from the ELISA bottom plate, while retaining the complete conformation of the antigen, thereby fully exposing the antigen epitope and improving the efficiency of antibody screening.

[0011] Specifically, the detection plate is a cell culture detection plate commonly used in the art, such as an ELISA plate.

[0012] As a further improvement, when the amino acid sequence of the SpyCatcher protein is SEQ ID No.1, the amino acid sequence of the Spytag is SEQ ID No.4; when the amino acid sequence of the SpyCatcher protein is SEQ ID No.2, the amino acid sequence of the Spytag is SEQ ID No.5; when the amino acid sequence of the SpyCatcher protein is SEQ ID No.3, the amino acid sequence of the Spytag is SEQ ID No.6.

[0013] In order to achieve the above object, the technical solution of a monoclonal antibody detection kit of the present invention is:

[0014] A monoclonal antibody detection kit comprises a detection plate, a SpyCatcher protein, a coating buffer, an antigen protein connected with a Spytag, and a coupling buffer; the antigen protein specifically binds to the monoclonal antibody.

[0015] The beneficial effect of the above scheme is that the detection kit of the monoclonal antibody of the present invention utilizes the peptide-protein chemical reaction generated by SpyCatcher / Spytag to fix the antigen protein on the ELISA plate, so that the binding of the antibody to the antigen is not affected by the bottom of the ELISA plate and maintains a certain distance from the ELISA bottom plate, while retaining the complete conformation of the antigen, which can significantly increase the number of monoclonal antibodies screened.

[0016] Specifically, the detection plate is a cell culture detection plate commonly used in the art, such as an ELISA plate.

[0017] More specifically, in actual operation, the SpyCatcher protein is first coated on the detection plate, and then the antigen protein connected with Spytag is added, and the antigen protein is indirectly fixed on the ELISA plate through the peptide-protein chemical reaction generated by the SpyCatcher protein and the Spytag.

[0018] Specifically, the connection can use a Linker to connect the Spytag and the antigen protein in series. The Linker is conventional in the art and can be a flexible Linker. The specific sequence is selected according to actual conditions.

[0019] As a further improvement, the coating buffer includes phosphate buffer or Tris hydrochloric acid buffer; the coupling buffer includes phosphate buffer or Tris hydrochloric acid buffer.

[0020] As a further improvement, when the amino acid sequence of the SpyCatcher protein is SEQ ID No.1, the amino acid sequence of the Spytag is SEQ ID No.4; when the amino acid sequence of the SpyCatcher protein is SEQ ID No.2, the amino acid sequence of the Spytag is SEQ ID No.5; when the amino acid sequence of the SpyCatcher protein is SEQ ID No.3, the amino acid sequence of the Spytag is SEQ ID No.6.

[0021] In order to achieve the above object, the technical solution of a method for efficiently screening monoclonal antibodies of the present invention is:

[0022] A highly efficient screening method for monoclonal antibodies comprises adding a liquid containing the monoclonal antibodies into a detection plate for ELISA screening; the detection plate is coated with SpyCatcher protein; the SpyCatcher protein is coupled to a Spytag connected with an antigen protein.

[0023] The beneficial effects of the above scheme are: the efficient screening method of monoclonal antibodies of the present invention uses the chemical reaction of peptide-protein generated by SpyCatcher protein and Spytag to indirectly fix the antigen protein on the ELISA plate, so that the antigen protein is at a certain distance from the bottom of the detection plate, and the antigen epitope is kept intact, which can effectively solve the problem of antigen coating causing the epitope to be covered and affecting the antibody binding during the hybridoma screening process, and provide convenience for the subsequent drug antibody screening and development, and can screen multiple types of antibodies, especially conformational epitope antibodies. At the same time, the binding of antibodies to antigens is not affected by the bottom of the ELISA plate, reducing the workload of repeated screening, and the overall operation is easy, short-term and efficient.

[0024] As a further improvement, the liquid containing the monoclonal antibody is derived from the cell supernatant obtained after the expansion culture of a single fusion hybridoma cell picked by a semi-solid culture method.

[0025] As a further improvement, mice were immunized with Spytag linked to antigen protein, and spleen cells were taken for fusion after the tail blood test was qualified to obtain hybridoma cells.

[0026] As a further improvement, the preparation of the detection plate includes the following steps:

[0027] (1) constructing a SpyCatcher expression vector and a Spytag expression vector connected to an antigen protein, and expressing and purifying them to obtain SpyCatcher protein and Spytag connected to an antigen protein;

[0028] (2) The SpyCatcher protein described in step (1) is coated onto an initial detection plate, and then the Spytag connected to the antigen protein is coupled to the SpyCatcher protein.

[0029] As a further improvement, when the amino acid sequence of the SpyCatcher protein is SEQ ID No.1, the amino acid sequence of the Spytag is SEQ ID No.4; when the amino acid sequence of the SpyCatcher protein is SEQ ID No.2, the amino acid sequence of the Spytag is SEQ ID No.5; when the amino acid sequence of the SpyCatcher protein is SEQ ID No.3, the amino acid sequence of the Spytag is SEQ ID No.6.

[0030] As a further improvement, the antigen protein is connected in series with Spytag.

[0031] As a further improvement, the antigen protein is FRα. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 The schematic diagram is a method for efficiently screening monoclonal antibodies of the present invention;

[0033] Figure 2 Part of the ELISA screening results in Example 1 of the present invention (wherein the left side is the SpyCatcher / Spytag-FRα experimental group, the number of positive wells exceeds the Spytag-FRα control group on the right, and the red circles are differentially cloned wells);

[0034] Figure 3 This is to verify the epitope characteristics recognized by the antibody in the experimental group in Example 2 of the present invention. DETAILED DESCRIPTION

[0035] Prior art When performing ELISA detection and screening of monoclonal antibodies, the screening antigen is coated on the ELISA plate, and the coating process causes the partial region of the antigen to be adsorbed on the ELISA plate, causing the antibody epitope that is partially bound to the region to be covered, affecting the binding of the monoclonal antibody to the antigen, ultimately affecting the number of positive monoclonal antibodies screened, and reducing the screening efficiency of the monoclonal antibody. Based on this, the present invention first provides a monoclonal antibody detection plate, using the chemical reaction of the peptide-protein produced by SpyCatcher / Spytag to fix the antigen protein on the ELISA plate, which can keep the antigen protein at a certain distance from the base plate, so that the antigen epitope is fully exposed. Then the antibody is not affected by the bottom of the ELISA plate when binding to the antigen, and keeps a certain distance from the ELISA base plate, while retaining the complete conformation of the antigen, so that the antigen epitope is fully exposed, and the antibody screening efficiency is improved.

[0036] Julio M. Fernandez's team evaluated the size of the amino acid profile, and calculated that the size of each amino acid profile was 0.4nm, and Spytag was 13aa. Dr. Mark Howarth's team identified the crystal profile of SpyCatcher, and the unit cell diameters were 3.162nm, 3.853nm, and 4.449nm. According to the above results, the present invention has experimentally confirmed that SpyCatcher / Spytag will form a certain height at the bottom of the test plate, and the SpyCatcher / Spytag has a large force, and it is not easy to detach from the test plate during subsequent multiple cleanings.

[0037] The present invention also provides an efficient screening method for monoclonal antibodies, wherein a liquid containing monoclonal antibodies is added to a test plate for ELISA screening; the test plate is coated with SpyCatcher protein; the SpyCatcher protein is coupled to a Spytag connected to an antigen protein, and the specific principle is as follows: Figure 1 shown.

[0038] The present invention is further described in detail below in conjunction with specific examples. Unless otherwise specified, the equipment and reagents used in each embodiment, experimental example and comparative example can be obtained from commercial sources.

[0039] Example 1 A highly efficient screening method for monoclonal antibodies

[0040] The highly efficient screening method for monoclonal antibodies in this embodiment is based on SpyCatcher / Spytag to screen human FRα monoclonal antibodies. The full-length human FRα protein is used as an immunogen to immunize mice, isolate hybridoma cells, and use the SpyCatcher / Spytag system to screen hybridoma cells. The specific implementation operations are as follows:

[0041] 1. Antigen design

[0042] According to the FRα amino acid sequence published by Uniprot, the accession number is P15328, FRα is a folate receptor protein encoding 254 amino acids. The extracellular domain is selected for expression, and codon optimization is performed through the codon optimization website to achieve more efficient expression of the recombinant protein.

[0043] 2. Vector construction and protein purification

[0044] (1) Construction of recombinant vector

[0045] Spytag003 was selected, and its amino acid sequence was shown in SEQ ID NO.6. Its C-terminus was connected to the N-terminus of the optimized FRα in series through a flexible linker. The amino acid sequence of the fusion protein was shown in SEQ ID NO.7. It was artificially synthesized and connected to pCDNA3.1 by homologous recombination using HindⅢ and EcoRⅠ restriction sites to construct the pCDNA3.1-Spytag-FRα recombinant vector.

[0046] The SpyCatcher003 nucleotide sequence (as shown in SEQ ID NO.3) was artificially synthesized and then recombinantly cloned into the pET28a expression vector using the restriction sites of BamHI and XhoI to construct the pET28a-SpyCatcher recombinant vector.

[0047] (2) Expression of recombinant proteins

[0048] The vector pET28a-SpyCatcher was transferred into BL21 (DE3) Escherichia coli competent cells. After verifying the positive strain, it was inoculated into 350 mL of LB liquid culture medium containing kanamycin resistance (50 μg / mL), cultured at 37°C until OD600 reached 0.4-0.8, IPTG was added at a final concentration of 0.4 mM, and expression was induced at 37°C for 5 h.

[0049] The vector pCDNA3.1-Spytag-FRα was transferred into E. coli TOP10, and the plasmid was extracted after the positive strain was verified. According to the instructions of gbico, the plasmid pCDNA3.1-Spytag-FRα was transiently transfected into a 20 mL cell shake flask, and the cell (HEK293 cell) density was adjusted to 3×10 6 / mL, HEK293 cell protein expression enhancer and feed were added 24 hours after transient transfection, and cell supernatant was collected 6-8 days later.

[0050] (3) Pre-treatment of recombinant protein purification

[0051] After centrifugation of the prokaryotic expression of pET28a-SpyCatcher, the bacteria were collected, and the fragmentation buffer was added, and ultrasonic fragmentation was performed (40W, 20min, working 3s, rest 3s), and centrifuged at 12000g for 10min. The supernatant solution was collected and filtered through a 0.45μm filter membrane for the next purification step.

[0052] The pCDNA3.1-Spytag-FRα supernatant was collected by centrifugation, impurities were removed by ultrafiltration, Tris buffer was added, and the supernatant was filtered through a 0.45 μm filter membrane for the next purification step.

[0053] The formulas of the fragmentation buffer and Tris buffer are as follows:

[0054] Disruption buffer: 20 mM Tris, 150 mM NaCl, 5 mM DTT, pH 7.6.

[0055] Tris buffer: 20 mM Tris, 150 mM NaCl, pH 7.6.

[0056] (4) Protein purification and identification

[0057] The above filtrate was purified by nickel agarose gel. When the filtrate was loaded onto the balanced nickel column, the flow rate was controlled to be 1 mL / min. Tris buffer was used for washing to remove unadsorbed proteins, and then 0.5 M imidazole eluent was used for gradient elution. The eluate was collected for SDS-PAGE protein identification, and samples with a purity greater than 90% were ultrafiltered and stored in Tris buffer. The obtained pET28a-SpyCatcher protein is collectively referred to as SpyCatcher hereinafter, and the obtained pCDNA3.1-Spytag-FRα protein is collectively referred to as Spytag-FRα hereinafter.

[0058] The formula of the elution solution is: 20 mM Tris, 150 mM NaCl, 0.5 M imidazole pH 7.6.

[0059] 3. Screening of FRα hybridoma cell lines and monoclonal antibody screening based on SpyCatcher / Spytag

[0060] (1) Animal immunization

[0061] The purified Spytag-FRα protein was mixed with an equal volume of Freund's complete adjuvant and immunized 6-8 week old BalB / c mice by subcutaneous injection at a dose of 100 μg / mouse. The second immunization was performed two weeks later. The antigen was emulsified with Freund's incomplete adjuvant and the immunization dose was the same as the first one. The method of intraperitoneal injection was adopted. After the second immunization, tail blood was collected and the serum titer was determined by gradient dilution by indirect ELISA method. The mice with the highest antibody titer were selected for tail vein pulse immunization at a dose of 50 μg / mouse.

[0062] (2) Cell fusion

[0063] Myeloma cells were SP2 / 0 derived from BalB / c, which were in the logarithmic growth phase when fused; the spleen of the mouse after shock immunization was removed aseptically to prepare a single cell suspension of spleen cells. Mouse spleen cells and myeloma cells were mixed at a ratio of 1:5, 1 mL of 50% PEG (pH 8.0) at 37°C was added dropwise for fusion, 3 mL of IMDM1640 was added, mixed, centrifuged and the supernatant was discarded, 10 mL of fetal bovine serum was added, 1 mL of 50×HAT was added, 2 mL of feeder layer cells were added, and mixed; 25 mL of semi-solid culture medium containing 2.1% nitrocellulose was added and mixed thoroughly, and poured into a cell plate, and incubated at 37°C with 5% CO 2 Culture in an incubator.

[0064] (3) Cell clone selection

[0065] Seven days after fusion, white spots can be observed on the surface of the culture medium by naked eye, which are cell clones under a microscope. Select independent, dispersed, round, and large clones and place them in a 96-well culture plate containing culture medium and place it in a 37°C, 5% CO 2 Continue to culture in the incubator. After 3 days, the cells have grown to the bottom of the 96-well plate. Take 100 μL of the supernatant and divide it into 2 parts for preliminary ELISA detection.

[0066] (4) Antigen treatment before ELISA screening of hybridoma cell clones

[0067] Spytag-FRα protein was directly coated on ELISA plates for screening of positive clones as a control group, and the subsequent screening was collectively referred to as the control group.

[0068] SpyCatcher was diluted to 1 μg / mL using coating buffer, 50 μL was coated on the ELISA plate, blocked with 5% BSA at room temperature for 1 h, cleared with TBST buffer 3-5 times, and incubated at 4°C for 16 h. After the coating process was completed, the plate was washed 3-5 times with TBST buffer and dried.

[0069] Spytag-FRα protein was diluted to 1 μg / mL using coupling buffer and added to the SpyCatcher wells at a molar ratio of 1:1. The mixture was allowed to stand at 30°C for 2 h. The TBST buffer was washed 3-5 times. After the SpyCatcher / Spytag-FRα coupling was completed, it was used for screening of positive clones as the experimental group, which is collectively referred to as the experimental group below.

[0070] The coating buffer and coupling condition buffer are both phosphate buffers with the formula: 190mM Na 2 HPO 4 , 10mM NaH 2 PO 4 ·2H 2O, 150 mM NaCl, pH 7.6.

[0071] (5) Hybridoma cell clone screening

[0072] The positive clone wells were counted, and the medium of all positive clone wells was completely replaced, and 200 μL of fresh complete medium containing feeder cells and 1% HT was added; the supernatant was taken after two days, and the control group and the experimental group were screened by the second ELISA at the same time.

[0073] The positive clone wells were counted, and the cells in the positive clone wells were transferred into a 24-well plate containing feeder cells and HT culture medium for culture. After 5 days, the supernatant was taken for the third ELISA test of the experimental group and the control group.

[0074] The ELISA detection process is as follows: pick up the culture supernatant of a single cell colony (100 μL) and add it to the ELISA plate coated and coupled in step (4), and incubate at 37°C for 1 hour. Then wash the wells 3-5 times with TBST buffer, add HRP-labeled goat anti-mouse IgG secondary antibody (1:5000 dilution), and incubate at 37°C for 1 hour. Wash the wells 3-5 times with TBST buffer, add 100 μL TMB substrate to each well, place it away from light for 5-10 minutes, and add 50 uL 2M H 2 SO 4 Stop the reaction and read on a microplate reader.

[0075] The results were counted, and the positive clones were transferred into cell culture flasks for expansion and cryopreservation.

[0076] In this embodiment, when screening FRα monoclonal antibodies based on SpyCatcher / Spytag, clones were picked in batches to 96-well plates, totaling 25 plates and 2349 clones. After expansion culture, ELISA experiments were performed on the experimental group and the control group, respectively. Among them, 539 positive clones were found in the experimental group, with a positive rate of 22.9%, and 302 positive clones were found in the control group, with a positive rate of 12.8%. The specific statistical results are shown in Table 1, and some ELISA screening results are shown in Table 1. Figure 2 shown. Figure 2 The left side is the SpyCatcher / Spytag-FRα experimental group, the number of positive wells is more than the Spytag-FRα control group on the right, and the red circles are differentially cloned wells.

[0077] Table 1 Statistics of ELISA screening of FRα monoclonal antibodies

[0078]

[0079] Example 2 Monoclonal Antibody Western Blot Verification

[0080] This example uses Western blot to verify the monoclonal antibody obtained in Example 1. According to the statistical results of positive clones in Example 1, there are 539 positive clones in the experimental group and 302 positive clones in the control group, and the experimental group screens 237 more clones than the control group. The supernatant of the 237 more positive clones in the experimental group than in the control group was taken, and the Western blot method was used to select some antibodies to verify the recognition characteristics of their epitopes. The specific implementation operation is as follows:

[0081] 1. Sample preparation

[0082] A 12% SDS-PAGE polyacrylamide gel was prepared, and the Spytag-FRα protein obtained in Example 1 was evenly mixed with a reducing 5× loading buffer and boiled for 10 minutes.

[0083] 2. SDS-PAGE electrophoresis, membrane transfer, and blocking

[0084] The prepared Spytag-FRα protein was loaded, 80V, 25min, and then 120V, 60min for protein electrophoresis. After the electrophoresis, the electrophoresis gel was removed, and a 0.2μm NC membrane was selected and transferred at 100V for 90min. After the transfer, the NC membrane was cut into small strips according to the width of the loading hole, placed in the antibody incubation box, washed 3 times with TBST, and blocked overnight with 5% skim milk.

[0085] 3. Antibody incubation

[0086] The supernatants of 237 hybridoma cells were selected and diluted (cell supernatants were diluted 1:1000), and then added to the antibody incubation box and incubated at 37°C for 1 hour. After rinsing with TBST 5 times, HRP-labeled Rabbit anti-mouse IgG (1:5000 dilution) was added, incubated at 37°C for 30 minutes, and then rinsed with TBST 5 times.

[0087] 4. Color rendering

[0088] After the NC film is taken out, it is placed on the darkroom plate of the exposure instrument, arranged neatly, the developer is evenly added to the film, exposed, and photographed for record.

[0089] 5. Results Analysis

[0090] In this example, 237 hybridoma cell supernatants (positive hybridomas screened in Example 1) were verified by WB, of which 45 could be used for WB experiments, accounting for 45 / 237, 19%. Some of the results are shown in Figure 3 shown.

[0091] Figure 3The left and right figures are partial results of the verification of the characteristics of monoclonal antibodies in antigen recognition epitopes. WB reaction means linear epitope recognition antibody, no reaction means conformational epitope recognition antibody, and the immunogen size is about 35KD. Therefore, preliminary statistics show that among the monoclonal antibodies screened by the method of the present invention, 81% of them recognize conformational epitopes, and 19% of them recognize linear epitopes.

[0092] Example 3 A monoclonal antibody detection plate

[0093] The monoclonal antibody detection plate of the present embodiment is an ELISA detection plate, which consists of a 96-well detection plate, a SpyCatcher protein coated on the detection plate, and a Spytag coupled to the SpyCatcher protein; the Spytag is connected to the FRα protein; the C-terminus of the Spytag and the N-terminus of the optimized FRα are connected in series through a flexible linker to form a fusion protein; the amino acid sequence of the SpyCatcher protein is shown in SEQ ID No.3, and the amino acid sequence of the fusion protein is shown in SEQ ID NO.7.

[0094] Example 4 A monoclonal antibody detection kit

[0095] The monoclonal antibody detection kit of this embodiment consists of a detection plate, a SpyCatcher protein, a coating buffer, a FRα protein (fusion protein) connected with a Spytag, a coupling buffer and a TBST buffer; the C-terminus of the Spytag and the N-terminus of the optimized FRα are connected in series through a flexible linker to form the fusion protein; the amino acid sequence of the SpyCatcher protein is shown in SEQ ID No.3, and the amino acid sequence of the fusion protein is shown in SEQ ID NO.7.

[0096] The coating buffer and coupling condition buffer are both phosphate buffers with the formula: 190mM Na 2 HPO 4 、10mMNaH 2 PO 4 ·2H 2 O, 150 mM NaCl, pH 7.6.

[0097] The above description is only an illustrative embodiment of the present invention and is not intended to limit the scope of the present invention. Any equivalent changes and modifications made by a person of ordinary skill in the art without departing from the concept and principle of the present invention shall fall within the scope of protection of the present invention.

Claims

1. A monoclonal antibody detection plate, characterized in that: The detection plate comprises a SpyCatcher protein coated on the detection plate and a Spytag coupled to the SpyCatcher protein; the Spytag is connected to an antigen protein.

2. The monoclonal antibody detection plate according to claim 1, characterized in that: When the amino acid sequence of the SpyCatcher protein is SEQ ID No.1, the amino acid sequence of the Spytag is SEQ ID No.4; when the amino acid sequence of the SpyCatcher protein is SEQ ID No.2, the amino acid sequence of the Spytag is SEQ ID No.5; when the amino acid sequence of the SpyCatcher protein is SEQ ID No.3, the amino acid sequence of the Spytag is SEQ ID No.

6.

3. A monoclonal antibody detection kit, characterized in that: The kit comprises a detection plate, a SpyCatcher protein, a coating buffer, an antigen protein connected with a Spytag, and a coupling buffer; the antigen protein is specifically combined with a monoclonal antibody.

4. The monoclonal antibody detection kit according to claim 3, characterized in that: The coating buffer comprises phosphate buffer or Tris hydrochloric acid buffer; the coupling buffer comprises phosphate buffer or Tris hydrochloric acid buffer.

5. The monoclonal antibody detection kit according to claim 3 or 4, characterized in that: When the amino acid sequence of the SpyCatcher protein is SEQ ID No.1, the amino acid sequence of the Spytag is SEQ ID No.4; when the amino acid sequence of the SpyCatcher protein is SEQ ID No.2, the amino acid sequence of the Spytag is SEQ ID No.5; when the amino acid sequence of the SpyCatcher protein is SEQ ID No.3, the amino acid sequence of the Spytag is SEQ ID No.

6.

6. A method for efficiently screening monoclonal antibodies, characterized in that: The liquid containing the monoclonal antibody is added to a detection plate for ELISA screening; the detection plate is coated with SpyCatcher protein; the SpyCatcher protein is coupled to a Spytag connected to an antigen protein.

7. The method for efficient screening of monoclonal antibodies according to claim 6, characterized in that: The liquid containing the monoclonal antibody is derived from the cell supernatant obtained after the expansion culture of a single fusion hybridoma cell picked by a semi-solid culture method.

8. The method for efficient screening of monoclonal antibodies according to claim 7, characterized in that: The preparation process of the hybridoma cells comprises the following steps: using Spytag connected with antigen protein to immunize mice, taking spleen cells for fusion after the tail blood test is qualified, and obtaining hybridoma cells.

9. The method for efficient screening of monoclonal antibodies according to claim 6, characterized in that: The preparation of the test plate comprises the following steps: (1) constructing a SpyCatcher expression vector and a Spytag expression vector connected to an antigen protein, and expressing and purifying them to obtain SpyCatcher protein and Spytag connected to an antigen protein; (2) The SpyCatcher protein described in step (1) is coated onto an initial detection plate, and then the Spytag connected to the antigen protein is coupled to the SpyCatcher protein.

10. The method for efficient screening of monoclonal antibodies according to any one of claims 6 to 9, characterized in that: When the amino acid sequence of the SpyCatcher protein is SEQ ID No.1, the amino acid sequence of the Spytag is SEQ ID No.4; when the amino acid sequence of the SpyCatcher protein is SEQ ID No.2, the amino acid sequence of the Spytag is SEQ ID No.5; when the amino acid sequence of the SpyCatcher protein is SEQ ID No.3, the amino acid sequence of the Spytag is SEQ ID No.6.